

Rabbit Anti-LMO2 [SP51]: RM0256, RM0256RTU7

Intended Use: For Research Use Only

Description: LMO2 is expressed in normal germinal center B-cells and in a subset of lymphomas derived from those cells in addition to bone marrow hematopoietic precursors and endothelial cells. LMO2 protein expression has also been shown to play an important role in the diagnosis of diffuse large B-cell lymphomas, regardless of rituximab treatment. It also plays a role in angiogenesis and hematopoiesis. It is weakly expressed in mantle zone B-cells but not in mantle cell or marginal zone lymphomas. It has been demonstrated that LMO2 is expressed in 70% of follicular lymphomas. These data suggest that anti-LMO2 is a useful adjunct in the diagnosis of follicular lymphoma (FL). As LMO2 appears not to be down regulated in higher grade FL or the interfollicular and diffuse components of FL, its utility in variant immunoarchitectural patterns of FL and in cases that lack CD10 and bcl2, is similar to that of HGAL.

Specifications


Clone: SP51
 Source: Rabbit
 Isotype: IgG
 Reactivity: Human
 Immunogen: A synthetic peptide corresponding to human LMO2 aa 1-100 N terminal
 Localization: Nucleus
 Formulation: Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
 Storage: Store at 2°- 8°C
 Applications: IHC, Flow Cyt., WB
 Package:

| Description | Catalog No. | Size |
|--------------------------|-------------|------|
| LMO2 [SP51] Concentrated | RM0256 | 1 ml |
| LMO2 [SP51] Prediluted | RM0256RTU7 | 7 ml |

IHC Procedure*

Positive Control Tissue: Normal lymph node
 Concentrated Dilution: 25-100
 Pretreatment: Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human lymph node tissue stained with anti-LMO2 using AEC

References:

1. The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow. Younes SF, et al. Am J Clin Pathol. May;135(5):697-708, 2011.
2. Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components. Younes SF, et al. Am J Surg Pathol. Sep;34(9):1266-76, 2010.
3. The expression of LMO2 protein in acute B-cell and myeloid leukemia. Cobanoglu U, et al. Hematology. Jun;15(3):132-4, 2010.